Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Lemaitre Vascular (LMAT) over the last 16 years, with Q3 2025 value amounting to $6.6 million.

  • Lemaitre Vascular's Change in Accured Expenses rose 26620.27% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 377202.07%. This contributed to the annual value of -$779000.0 for FY2024, which is 11693.85% down from last year.
  • Per Lemaitre Vascular's latest filing, its Change in Accured Expenses stood at $6.6 million for Q3 2025, which was up 26620.27% from $4.0 million recorded in Q2 2025.
  • Lemaitre Vascular's 5-year Change in Accured Expenses high stood at $6.6 million for Q3 2025, and its period low was -$5.3 million during Q1 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $469000.0 (2022), whereas its average is $424105.3.
  • Per our database at Business Quant, Lemaitre Vascular's Change in Accured Expenses plummeted by 23723.49% in 2021 and then soared by 915714.29% in 2023.
  • Lemaitre Vascular's Change in Accured Expenses (Quarter) stood at -$1.2 million in 2021, then surged by 140.19% to $469000.0 in 2022, then soared by 400.21% to $2.3 million in 2023, then decreased by 24.98% to $1.8 million in 2024, then soared by 273.69% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $4.0 million for Q2 2025, and -$5.3 million during Q1 2025.